Intl Fcstone Inc. acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 32,909 shares of the company’s stock, valued at approximately $4,354,000. Johnson & Johnson makes up about 1.4% of Intl Fcstone Inc.’s holdings, making the stock its 3rd largest position.
Several other hedge funds also recently bought and sold shares of the company. State Street Corp lifted its holdings in Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares in the last quarter. BlackRock Inc. lifted its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Johnson & Johnson by 717.9% in the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after purchasing an additional 3,289,763 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its holdings in Johnson & Johnson by 47.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after purchasing an additional 2,581,562 shares in the last quarter. 65.89% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have recently issued reports on the company. Piper Jaffray Companies reaffirmed a “hold” rating and set a $120.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 4th. Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price objective on the stock. in a report on Monday, September 18th. Stifel Nicolaus upped their price objective on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. UBS reaffirmed a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a report on Thursday, August 31st. Finally, Wells Fargo & Company raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $140.00 to $149.00 in a report on Monday, October 9th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $145.04.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.68 EPS. analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.36%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.